Avicena ALS drug flunks Phase III trial

The Avicena Group of Palo Alto, CA, says its Phase III trial of ALS-02 for Lou Gehrig's disease failed to demonstrate a benefit over placebos. But researchers noted that data analysis demonstrated "a positive trend toward decreased mortality in subjects receiving ALS-02."

"We are very interested in further exploring this trend toward decreased mortality," said Belinda Tsao-Nivaggioli, Ph.D., Avicena's CEO. "We intend to explore whether these findings can be expected to impact the remaining regulatory path for the compound."

- here's the release for more information

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.